Variants of human tissue-type plasminogen activator substituted at the protease cleavage site and glycosylation sites, and truncated at the n- and c-termini

Nancy Haigwood, Guy T. Mullenbach, Gregory K. Moore, Lucy E. Desjardin, Azita Tabrizi, Sheryl L. Brown-Shimer, H. Stauß, H. A. Stöhr, Eric Paul Paques

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Mutations were directed to specific regions of the human tissue-type plasminogen activator (t-PA) gene in an effort to better define structure-function relationships of the enzyme. Three types of modifications were effected by in vitro mutagenesis: elimination of glycosylation sites; substitutions of amino acids at the cleavage site for conversion of single-chain t-PA to two-chain t-PA; and truncations of the N- and C-termini. Thirteen variants were purified from permanent CHO cell lines and analyzed for specific activity, fibrin stimulation, fibrin binding, inhibition by plasminogen activator inhibitor-2 (PAI-2) and half-life. The results of these analyses are: (i) variants with carbohydrate-depleted kringle domains possessed higher specific activities than wild-type t-PA; (ii) a cleavage site variant substituted at Arg275 with Gly had greatly reduced specific activity; (iii) two variants substituted at Lys277 exhibited altered interactions with PAI-2; (iv) the variant with a truncated C-terminus had reduced activity in the absence of fibrin; and (v) no variants had significantly altered half-lives. In order to test the effects of combining mutations, four additional variants were produced. Each combination variant retained at least one of the altered properties observed in the original variants, and in three of the variants the diverse properties were additive.

Original languageEnglish (US)
Pages (from-to)611-620
Number of pages10
JournalProtein Engineering, Design and Selection
Volume2
Issue number8
DOIs
StatePublished - Aug 1989
Externally publishedYes

Fingerprint

Glycosylation
Plasminogen Activators
Tissue Plasminogen Activator
Fibrin
Plasminogen Activator Inhibitor 2
Peptide Hydrolases
Tissue
Mutagenesis
Carbohydrates
Kringles
Amino acids
Mutation
Substitution reactions
Enzymes
CHO Cells
Genes
Amino Acid Substitution
Half-Life
Amino Acids
Cell Line

Keywords

  • Cleavage site variants
  • Glycosylation variants
  • Plasminogen activator
  • Site-directed mutagenesis
  • Truncation variants

ASJC Scopus subject areas

  • Pharmacology
  • Neuroscience(all)
  • Immunology and Microbiology(all)
  • Molecular Biology
  • Bioengineering
  • Biotechnology
  • Biochemistry

Cite this

Variants of human tissue-type plasminogen activator substituted at the protease cleavage site and glycosylation sites, and truncated at the n- and c-termini. / Haigwood, Nancy; Mullenbach, Guy T.; Moore, Gregory K.; Desjardin, Lucy E.; Tabrizi, Azita; Brown-Shimer, Sheryl L.; Stauß, H.; Stöhr, H. A.; Paques, Eric Paul.

In: Protein Engineering, Design and Selection, Vol. 2, No. 8, 08.1989, p. 611-620.

Research output: Contribution to journalArticle

Haigwood, Nancy ; Mullenbach, Guy T. ; Moore, Gregory K. ; Desjardin, Lucy E. ; Tabrizi, Azita ; Brown-Shimer, Sheryl L. ; Stauß, H. ; Stöhr, H. A. ; Paques, Eric Paul. / Variants of human tissue-type plasminogen activator substituted at the protease cleavage site and glycosylation sites, and truncated at the n- and c-termini. In: Protein Engineering, Design and Selection. 1989 ; Vol. 2, No. 8. pp. 611-620.
@article{65e0aa7fe3854d40beb946af2aad55a2,
title = "Variants of human tissue-type plasminogen activator substituted at the protease cleavage site and glycosylation sites, and truncated at the n- and c-termini",
abstract = "Mutations were directed to specific regions of the human tissue-type plasminogen activator (t-PA) gene in an effort to better define structure-function relationships of the enzyme. Three types of modifications were effected by in vitro mutagenesis: elimination of glycosylation sites; substitutions of amino acids at the cleavage site for conversion of single-chain t-PA to two-chain t-PA; and truncations of the N- and C-termini. Thirteen variants were purified from permanent CHO cell lines and analyzed for specific activity, fibrin stimulation, fibrin binding, inhibition by plasminogen activator inhibitor-2 (PAI-2) and half-life. The results of these analyses are: (i) variants with carbohydrate-depleted kringle domains possessed higher specific activities than wild-type t-PA; (ii) a cleavage site variant substituted at Arg275 with Gly had greatly reduced specific activity; (iii) two variants substituted at Lys277 exhibited altered interactions with PAI-2; (iv) the variant with a truncated C-terminus had reduced activity in the absence of fibrin; and (v) no variants had significantly altered half-lives. In order to test the effects of combining mutations, four additional variants were produced. Each combination variant retained at least one of the altered properties observed in the original variants, and in three of the variants the diverse properties were additive.",
keywords = "Cleavage site variants, Glycosylation variants, Plasminogen activator, Site-directed mutagenesis, Truncation variants",
author = "Nancy Haigwood and Mullenbach, {Guy T.} and Moore, {Gregory K.} and Desjardin, {Lucy E.} and Azita Tabrizi and Brown-Shimer, {Sheryl L.} and H. Stau{\ss} and St{\"o}hr, {H. A.} and Paques, {Eric Paul}",
year = "1989",
month = "8",
doi = "10.1093/protein/2.8.611",
language = "English (US)",
volume = "2",
pages = "611--620",
journal = "Protein Engineering, Design and Selection",
issn = "1741-0126",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Variants of human tissue-type plasminogen activator substituted at the protease cleavage site and glycosylation sites, and truncated at the n- and c-termini

AU - Haigwood, Nancy

AU - Mullenbach, Guy T.

AU - Moore, Gregory K.

AU - Desjardin, Lucy E.

AU - Tabrizi, Azita

AU - Brown-Shimer, Sheryl L.

AU - Stauß, H.

AU - Stöhr, H. A.

AU - Paques, Eric Paul

PY - 1989/8

Y1 - 1989/8

N2 - Mutations were directed to specific regions of the human tissue-type plasminogen activator (t-PA) gene in an effort to better define structure-function relationships of the enzyme. Three types of modifications were effected by in vitro mutagenesis: elimination of glycosylation sites; substitutions of amino acids at the cleavage site for conversion of single-chain t-PA to two-chain t-PA; and truncations of the N- and C-termini. Thirteen variants were purified from permanent CHO cell lines and analyzed for specific activity, fibrin stimulation, fibrin binding, inhibition by plasminogen activator inhibitor-2 (PAI-2) and half-life. The results of these analyses are: (i) variants with carbohydrate-depleted kringle domains possessed higher specific activities than wild-type t-PA; (ii) a cleavage site variant substituted at Arg275 with Gly had greatly reduced specific activity; (iii) two variants substituted at Lys277 exhibited altered interactions with PAI-2; (iv) the variant with a truncated C-terminus had reduced activity in the absence of fibrin; and (v) no variants had significantly altered half-lives. In order to test the effects of combining mutations, four additional variants were produced. Each combination variant retained at least one of the altered properties observed in the original variants, and in three of the variants the diverse properties were additive.

AB - Mutations were directed to specific regions of the human tissue-type plasminogen activator (t-PA) gene in an effort to better define structure-function relationships of the enzyme. Three types of modifications were effected by in vitro mutagenesis: elimination of glycosylation sites; substitutions of amino acids at the cleavage site for conversion of single-chain t-PA to two-chain t-PA; and truncations of the N- and C-termini. Thirteen variants were purified from permanent CHO cell lines and analyzed for specific activity, fibrin stimulation, fibrin binding, inhibition by plasminogen activator inhibitor-2 (PAI-2) and half-life. The results of these analyses are: (i) variants with carbohydrate-depleted kringle domains possessed higher specific activities than wild-type t-PA; (ii) a cleavage site variant substituted at Arg275 with Gly had greatly reduced specific activity; (iii) two variants substituted at Lys277 exhibited altered interactions with PAI-2; (iv) the variant with a truncated C-terminus had reduced activity in the absence of fibrin; and (v) no variants had significantly altered half-lives. In order to test the effects of combining mutations, four additional variants were produced. Each combination variant retained at least one of the altered properties observed in the original variants, and in three of the variants the diverse properties were additive.

KW - Cleavage site variants

KW - Glycosylation variants

KW - Plasminogen activator

KW - Site-directed mutagenesis

KW - Truncation variants

UR - http://www.scopus.com/inward/record.url?scp=0024340805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024340805&partnerID=8YFLogxK

U2 - 10.1093/protein/2.8.611

DO - 10.1093/protein/2.8.611

M3 - Article

VL - 2

SP - 611

EP - 620

JO - Protein Engineering, Design and Selection

JF - Protein Engineering, Design and Selection

SN - 1741-0126

IS - 8

ER -